Vir Biotechnology Inc (VIR) Actualités

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the...

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

– Designations aim to expedite the development and review of promising therapies for serious conditions with unmet medical needs – – Phase 3...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1...

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to...

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 – – Undetectable...

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant...

Form 4 - Statement of changes in beneficial ownership of securities

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

– 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]